The original contract in Alzheimer’s disease was announced on 5 July 2017 and this change order reflects an extension of the contract term from September 2020 to May 2021 and the addition of new clinical sites.
The latest amendment results in a total change in the contract value of €0.5m or 65% above the original value of €0.8m.
Change orders often occur as part of the normal course of multi-year contracts, as the scope of services that IXICO provides can be expanded or extended during the term of a clinical trial.
IXICO CEO Giulio Cerroni said: “We are delighted to announce a further extension and expansion of this project. This change order and increase in contract value, demonstrates how closely we work with our biopharmaceutical clients to expand the services we provide to their clinical development programmes.”
IXICO is dedicated to delivering insights in neuroscience. The company’s mission is to transform the progression of our clients’ neurodegenerative therapeutic pipeline through the application of novel medical imaging and mobile health digital technologies.
IXICO’s specialist data analytics services are used by the global pharmaceutical industry to interpret brain scan data and digital biomarkers to enable better trial design, site qualification, patient selection and clinical outcomes.
The company provides technology-enabled services across all phases of clinical trial process evaluation. Its integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions.
IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products.
Source: Company Press Release.